OptimizeRx (OPRX) Stock Price, News & Analysis

Company Overview

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: $12.01 to $13.44
• 50-Day Range: $7.44 to $12.64
• 52-Week Range: $3.78 to $13.39
• Volume: 600,728 shs
• Average Volume: 282,632 shs
• Market Capitalization: $244.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.38
• Consensus Rating: Moderate Buy

OptimizeRx Stock Analysis - MarketRank™

OptimizeRx scored higher than 48% of companies evaluated by MarketBeat, and ranked 414th out of 656 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

OptimizeRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OptimizeRx are expected to grow in the coming year, from ($0.33) to ($0.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OptimizeRx is -9.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OptimizeRx is -9.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OptimizeRx has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.48% of the float of OptimizeRx has been sold short.

Short Interest Ratio / Days to Cover

OptimizeRx has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OptimizeRx has recently decreased by 10.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OptimizeRx does not currently pay a dividend.

Dividend Growth

OptimizeRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.48% of the float of OptimizeRx has been sold short.

Short Interest Ratio / Days to Cover

OptimizeRx has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OptimizeRx has recently decreased by 10.38%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.38

News Sentiment

OptimizeRx has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Computer and Technology companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for OptimizeRx this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for OPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, OptimizeRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,442,701.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 5.60% of the stock of OptimizeRx is held by insiders.

Percentage Held by Institutions

76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OPRX Stock Analysis - Frequently Asked Questions

How have OPRX shares performed this year?

OptimizeRx's stock was trading at $4.86 at the start of the year. Since then, OPRX stock has increased by 172.0% and is now trading at $13.22.
View the best growth stocks for 2025 here.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) released its quarterly earnings data on Monday, May, 12th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.19. The business earned $21.93 million during the quarter, compared to the consensus estimate of $18.69 million. OptimizeRx had a negative trailing twelve-month return on equity of 4.92% and a negative net margin of 27.41%.
Read the conference call transcript.

Who are OptimizeRx's major shareholders?

OptimizeRx's top institutional investors include Whetstone Capital Advisors LLC (8.16%), Royce & Associates LP (5.38%), Blair William & Co. IL (3.41%) and Rice Hall James & Associates LLC (3.12%). Insiders that own company stock include William J Febbo, James Paul Lang, Marion Odence-Ford, Stephen L Silvestro, Edward Stelmakh and Ellen O'connor Vos.
View institutional ownership trends.

How do I buy shares of OptimizeRx?

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 6/03/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: Business services, not elsewhere classified
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:OPRX
• CIK: 1448431
• Web: www.optimizerx.com
• Phone: (248) 651-6568
• Fax: 248-453-5529
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.38
• High Stock Price Target: $16.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: -21.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.57 million
• Net Margins: -27.41%
• Pretax Margin: -37.84%
• Return on Equity: -4.92%
• Return on Assets: -3.41%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 3.23
• Quick Ratio: 3.23

Sales & Book Value

• Annual Sales: $94.37 million
• Price / Sales: 2.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.97 per share
• Price / Book: 1.90

Miscellaneous

• Outstanding Shares: 18,495,000
• Free Float: 17,297,000
• Market Cap: $244.50 million
• Optionable: Optionable
• Beta: 1.28